Business Wire

CA-VERIMATRIX

18.3.2024 17:46:33 CET | Business Wire | Press release

Share
Verimatrix Releases Counterspy as a New Anti-Piracy Solution with First-Ever Defensive Capabilities

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced general availability of its new Verimatrix Counterspy anti-piracy solution -- the most advanced anti-piracy technology seen in the past decade.

Counterspy leverages technology first developed by the company's cybersecurity team back in 2021 to offer an innovative new way to counter the rise in video piracy in an era where streaming apps are prevalent. Counterspy is a standalone product within Verimatrix's anti-piracy team, engineered to prevent video content theft, shield apps from attack, and provide ongoing piracy threat prediction, detection and response services.

Counterspy goes beyond traditional methods to ensure top-tier security for media app subscribers, safeguarding content across various devices. It fills the gap in authentication created by the shift from operator-controlled set top box hardware to retail or app-based OTT clients, allowing operators to distribute content confidently while preventing piracy. With Counterspy, each app instance is authenticated and tied to a specific subscriber, ensuring transparency and control over access. By safeguarding the authentication token from theft or manipulation, Counterspy prevents abuse and ensures legitimate access to content, going above and beyond traditional DRM vendors.

What makes Counterspy stand out:

  • Unique Protection and Threat Detection from the Video Service Provider to the Consumer Device: Verimatrix Counterspy effortlessly brings security into the unmanaged consumer device via the video app, something that has been lacking since the explosion of OTT streaming services that use consumers’ own devices. Verimatrix combined the best of its anti-piracy technologies with its cybersecurity innovations to create a bold new approach to tackling the piracy problem – a breakthrough leap forward.
  • AI/ML-Driven Real-Time Protection: Leveraging the latest in artificial intelligence and machine learning, Counterspy can quickly identify piracy signals and cybersecurity threats, allowing for the real-time deployment of countermeasures.
  • Multi-Layered Security Approach: Counterspy builds on proven technologies such as DRM and watermarking, with a new generation of sophisticated app protection and piracy monitoring tools to detect suspicious activity. This allows video service providers to pinpoint suspicious behavior at its source – as it’s happening – to thwart bad actors without impacting the experience of legitimate service subscribers. By shielding the app, Counterspy also protects personal information and payment card details belonging to video service subscribers. This multi-layered approach to video content + app security, along with the ability to deploy real-time anti-piracy countermeasures, allows streaming operators to continuously evolve their response to emerging threats – staying one step ahead of the pirates.

“With our release of Counterspy, Verimatrix is at the forefront of the innovation needed to fight today’s sophisticated pirates within a vastly connected content viewing ecosystem,” said Andrew Bear, head of anti-piracy business at Verimatrix. “Yesterday’s security approaches are no longer enough to protect both revenue and content. Counterspy enables streaming operators to immediately fight back against pirates that seek to use the latest and often unnoticed business-draining techniques. We see Counterspy as a giant leap forward for security in the M&E industry because it can be directly linked to millions of dollars in prevented piracy-related losses as well as notable operating cost savings.”

For operators, Counterspy targets piracy and revenue leakage, enhances content security and app protections, and helps prevent the compromise of user data. A Verimatrix telco customer who deployed an early release version of Counterspy realized an OPEX savings of $300,000, and they prevented direct piracy losses of $21 million in one year. Counterspy's design for speedy and straightforward integration into streaming video clients allows operators to detect and efficiently counteract piracy directly at its source – serving as an "autonomous security solution" that stands in stark contrast to traditional methods.

Counterspy is part of the Verimatrix Streamkeeper suite of security solutions and can be flexibly deployed alongside other Verimatrix technologies, including Multi-DRM and Watermarking. Operators can schedule a demo by clicking here.

A live webinar is scheduled to take place on March 19 at 5 p.m. CET / 9 a.m. PST with security experts from Verimatrix and sports leader beIN discussing piracy in today’s video ecosystem and showing why a combination of classic video protection and cybersecurity is key for success. Presenters include Lee Kent from beIN, Klaus Schenk, SVP Security and Threat Research at Verimatrix, and Maria Malinkowitsch, VP Video Protection Business at Verimatrix. Register here.

A companion white paper has also been made available for download, "Securing the Streaming Seas: Verimatrix Counterspy's Superior Defense Against Piracy In a World Dominated by Video Apps."

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318045012/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye